Targeting the major regulator of mitosis.

APC/C;mitosis;cancer;mitotic inhibitors;chemotherapy;drug development

J. Mason Hoffman

University:University of Louisville

Department:Pharmacology and Toxicology

关键词: APC/C;    mitosis;    cancer;    mitotic inhibitors;    chemotherapy;    drug development;   

Others  :  https://ir.library.louisville.edu/cgi/viewcontent.cgi?article=3885&context=etd

美国|英语

来源: The Universite of Louisville's Institutional Repository

【 摘 要 】

Mitosis-inhibiting chemotherapeutics (e.g. taxanes) are frequently used to treat multiple cancer types. Recently, there has been much concern about the limited success of these drugs due to resistance and a lack of molecular targets. Thus, there is high demand for new drugs with diverse cellular targets. Targeting the regulators of mitosis is a promising approach. The anaphase promoting complex/cyclosome (APC/C) is an E3 ubiquitin ligase that controls cell cycle progression at multiple points. The interaction of ANAPC2 and ANAPC11, catalytic core subunits, is necessary for APC/C function. An in silico approach was used to identify compounds predicted to prevent assembly of ANAPC2 and ANAPC11, causing APC/C inhibition and mitotic arrest. Several of the predicted compounds possess cytotoxic properties in multiple cancer cell types. These hit compounds induce mitotic arrest and cell death in malignant, but not non-malignant cells. Additionally, hit compounds are effective in taxane-resistant cells.